Each year lung cancer causes over 1.59 million deaths worldwide, more than any other cancer. Approximately 85% of lung cancer cases are a type of lung cancer called non-small cell lung cancer, and of these 5% are anaplastic lymphoma kinase (ALK)-positive. This type of lung cancer can be effectively targeted by a type of drug called an ALK-inhibitor, but how do they work?